Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx

Fabrice Andre, Nofisat Ismaila, N. Lynn Henry, Mark R. Somerfield, Robert C. Bast, William Barlow, Deborah E. Collyar, M. Elizabeth Hammond, Nicole M. Kuderer, Minetta C. Liu, Catherine Van Poznak, Antonio C Wolff, Vered Stearns

Research output: Contribution to journalArticle

Abstract

PURPOSE: This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy. METHODS: ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS: For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines.

Original languageEnglish (US)
Pages (from-to)1956-1964
Number of pages9
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume37
Issue number22
DOIs
StatePublished - Aug 1 2019

Fingerprint

Practice Guidelines
Biomarkers
Breast Neoplasms
Recurrence
Therapeutics
Guidelines
Disease-Free Survival
Publications
Hormones
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer : ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. / Andre, Fabrice; Ismaila, Nofisat; Henry, N. Lynn; Somerfield, Mark R.; Bast, Robert C.; Barlow, William; Collyar, Deborah E.; Hammond, M. Elizabeth; Kuderer, Nicole M.; Liu, Minetta C.; Van Poznak, Catherine; Wolff, Antonio C; Stearns, Vered.

In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, No. 22, 01.08.2019, p. 1956-1964.

Research output: Contribution to journalArticle

Andre, Fabrice ; Ismaila, Nofisat ; Henry, N. Lynn ; Somerfield, Mark R. ; Bast, Robert C. ; Barlow, William ; Collyar, Deborah E. ; Hammond, M. Elizabeth ; Kuderer, Nicole M. ; Liu, Minetta C. ; Van Poznak, Catherine ; Wolff, Antonio C ; Stearns, Vered. / Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer : ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 ; Vol. 37, No. 22. pp. 1956-1964.
@article{12f7aef7fddd484588f7dbb21e128db6,
title = "Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx",
abstract = "PURPOSE: This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy. METHODS: ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS: For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines.",
author = "Fabrice Andre and Nofisat Ismaila and Henry, {N. Lynn} and Somerfield, {Mark R.} and Bast, {Robert C.} and William Barlow and Collyar, {Deborah E.} and Hammond, {M. Elizabeth} and Kuderer, {Nicole M.} and Liu, {Minetta C.} and {Van Poznak}, Catherine and Wolff, {Antonio C} and Vered Stearns",
year = "2019",
month = "8",
day = "1",
doi = "10.1200/JCO.19.00945",
language = "English (US)",
volume = "37",
pages = "1956--1964",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

T2 - ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx

AU - Andre, Fabrice

AU - Ismaila, Nofisat

AU - Henry, N. Lynn

AU - Somerfield, Mark R.

AU - Bast, Robert C.

AU - Barlow, William

AU - Collyar, Deborah E.

AU - Hammond, M. Elizabeth

AU - Kuderer, Nicole M.

AU - Liu, Minetta C.

AU - Van Poznak, Catherine

AU - Wolff, Antonio C

AU - Stearns, Vered

PY - 2019/8/1

Y1 - 2019/8/1

N2 - PURPOSE: This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy. METHODS: ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS: For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines.

AB - PURPOSE: This focused update addresses the use of Oncotype DX in guiding decisions on the use of adjuvant systemic therapy. METHODS: ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease-free survival in women with Oncotype DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Oncotype DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS: For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85070788790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070788790&partnerID=8YFLogxK

U2 - 10.1200/JCO.19.00945

DO - 10.1200/JCO.19.00945

M3 - Article

VL - 37

SP - 1956

EP - 1964

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -